<DOC>
	<DOCNO>NCT02550067</DOCNO>
	<brief_summary>The ECHO Study open-label randomize clinical trial compare three highly effective , reversible method contraception ( include non-hormonal method ) evaluate whether link use method increase risk acquire HIV infection . A randomized clinical trial among 7,800 woman four country , ECHO deliver evidence support guide individual , policy programmatic decision contraception woman risk acquire HIV infection .</brief_summary>
	<brief_title>The Evidence Contraceptive Options HIV Outcomes Trial</brief_title>
	<detailed_description>Approximately 7800 sexually active , HIV-negative woman , 16-35 year old , seek effective contraception , willing randomize study arm , desire pregnancy duration study participation randomly allocate one three study arm 1:1:1 ratio : depot medroxyprogesterone acetate ( DMPA ) , levonorgestrel ( LNG ) implant , copper intrauterine device ( IUD ) . Enrollment require estimate 18 month total duration clinical portion study estimate 36 month . The primary objective compare risk HIV acquisition woman randomize DMPA , levonorgestrel ( LNG ) implant , copper IUDs . Secondary objective compare : 1 ) pregnancy rate among woman randomize DMPA , LNG implant , copper IUDs , 2 ) rate serious adverse event among woman randomize DMPA , LNG implant , copper IUDs , 3 ) rate adverse event lead method discontinuation among woman randomize DMPA , LNG implant , copper IUDs , 4 ) contraceptive method continuation rate among woman randomize DMPA , LNG implant , copper IUDs . Tertiary objective evaluate : 1 ) whether age modifies relationship three contraceptive method HIV acquisition , 2 ) whether HSV-2 status modifies relationship three contraceptive method HIV acquisition , 3 ) early HIV disease progression among sero-converters randomize DMPA , LNG implant , copper IUDs .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>1635 year age ( previously pregnant 16 17 year old , permissible national regulation local IRB approval ) HIVseronegative Wants use effective contraception Is able willing provide write informed consent Agrees randomize either DMPA , LNG implant , copper IUD Agrees use assign method 18 month Agrees follow study requirement Intends stay study area next 18 month , willing able provide adequate locator information If recent third trimester birth , least 6 week postpartum Is sexually active ( vaginal sex within last 3 month ) pregnant within last 3 month Agrees participate study drug vaccine clinical research study participate study . Reported medical contraindication ( WHO MEC Category 3 4 ) DMPA , LNG implant , copper IUDs , include : recent septic abortion ; suspicious unexplained vaginal bleeding ; breast , cervical , uterine , ovarian cancer ; high BP heart disease , venous thromboembolism , stroke , diabetes ; liver disease liver tumour ; use liver enzyme induce medication Is find pelvic tuberculosis uterine fibroid distortion uterine cavity pelvic exam Has untreated mucus purulent cervicitis exam , untreated pelvic inflammatory disease ( PID ) , untreated know gonorrhea chlamydia Has receive DMPA NETEn injection last 6 month Has use implant IUD last 6 month Is pregnant intend become pregnant next 18 month Has hysterectomy sterilization Has previously participate study Has condition ( social medical ) opinion investigator would make study participation unsafe complicate data interpretation .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>DepoLevonorgestrel</keyword>
	<keyword>Contraception</keyword>
	<keyword>DMPA</keyword>
	<keyword>Copper IUD</keyword>
	<keyword>Levonorgestrel implant</keyword>
	<keyword>IUD</keyword>
</DOC>